E. La Rocca
University of Milan
Acute toxicityOncologyMonoclonalObservational studyHormone receptorAzathioprineAdjuvant therapyPancreas transplantationDiscontinuationContouringComorbidityKidneyImmunosuppressionPrimary tumorKidney transplantationLymph nodeTransplantationBreast cancerDiabetes mellitusMedicine
8Publications
1H-index
4Citations
Publications 8
Newest
#1E. La Rocca (University of Milan)H-Index: 1
Last. Maria De SantisH-Index: 32
view all 13 authors...
AIM: To assess the impact of age, comorbidities and endocrine therapy (ET) in older breast cancer (BC) patients treated with hypofractionated radiotherapy (Hypo-RT). METHODS: From June 2009 to December 2017, we enrolled in this study 735 ER-positive BC patients (stage pT1-T2, pNx-1, M0 and age ≥ 65 years) receiving hypo-RT and followed them until September 2019. Baseline comorbidities included in the hypertension-augmented Charlson Comorbidity Index were retrospectively retrieved. Logistic regre...
1 CitationsSource
#1M.C. De SantisH-Index: 1
#1M. De SantisH-Index: 13
Last. S. Di CosimoH-Index: 15
view all 16 authors...
Background Primary tumor characteristics, which are readily available to all clinicians, may aid in selecting the optimal adjuvant therapy for patients with breast cancer (BC). Herein, we investigated the relationship between tumor size, hormone receptor and HER2 status, Ki67 and age with axillary lymph node metastases (ALNM) in early-BC patients.
Source
#1E. La RoccaH-Index: 1
#2Laura LozzaH-Index: 18
Last. M. De SantisH-Index: 13
view all 11 authors...
To report acute toxicities in breast cancer (BC) patients (pts) recruited in a prospective trial and treated with accelerated partial-breast irradiation (APBI) using Volumetric Modulated Arc Therapy (VMAT) delivered with a hypofractionated schedule. From March 2014 to June 2019, pts with early-stage BC (Stage I), who underwent breast conservative surgery (BCS), were recruited in a prospective study started at the National Cancer Institute of Milan. Pts received APBI with a hypofractionated sched...
Source
#1E. La RoccaH-Index: 1
Last. M. De SantisH-Index: 13
view all 13 authors...
Source
#1E. La RoccaH-Index: 1
Last. M. De SantisH-Index: 13
view all 13 authors...
Source
#1E. La RoccaH-Index: 1
Last. M. De SantisH-Index: 13
view all 10 authors...
Source
#1M. De SantisH-Index: 13
Last. Laura LozzaH-Index: 18
view all 13 authors...
Source
#1M. Bernardi (University of Milan)H-Index: 1
#2E. La Rocca (University of Milan)H-Index: 1
Last. A. Secchi (University of Milan)H-Index: 17
view all 9 authors...
Monoclonal components (MC) are detected in as high as 30 % of renal transplant recipients. Our aim was to evaluate the incidence, relevance and consequence of monoclonal components in patients with Type I (insulin-dependent) diabetes who received kidney (n = 22), kidney and whole pancreas (n = 41), kidney and segmental pancreas (n = 24) and kidney and islets (n = 12) transplants. Immunosuppression was based on prophylactic anti-lymphocyte globulins, corticosteroids, azathioprine and cyclosporin ...
3 CitationsSource
1
Close Researchers